SCHEDULE: Cosciens Biopharma: Puccetti Reduces Stake and Role

Peter Puccetti has sold his interest in Goodwood Inc., significantly reducing his beneficial ownership in Cosciens Biopharma to 0.5%.

Summary

• Peter Puccetti and Puccetti Funds Management Inc. filed an amendment to their Schedule 13D following the sale of Puccetti's interest in Goodwood Inc. to Nour Private Management Inc.
• The transaction, effective March 1, 2026, resulted in the termination of the Joint Filing Agreement between the parties.
• Puccetti's beneficial ownership in Cosciens Biopharma Inc. decreased from approximately 8.2% (257,257 shares) to 0.5% (15,687 shares).
• Puccetti remains the interim Chief Executive Officer and Chairman of the Board of Cosciens Biopharma.
• The company is actively pursuing a voluntary delisting from NASDAQ and termination of U.S. reporting obligations.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while the governance dispute is resolved, the significant reduction in the CEO's stake and the move to delist suggest a period of transition and reduced public market visibility.

Positives

• The resolution of the shareholder dispute and board reconstitution in 2025 has provided a stable governance structure.
• The company is actively seeking to reduce administrative costs by pursuing the termination of U.S. SEC reporting obligations.
• The transition of Goodwood's investment management to Nour Private Management provides clarity on the future direction of the remaining Goodwood Fund shares.

Negatives

• Significant reduction in the stake held by the interim CEO and Chairman, which may be perceived as a lack of long-term alignment with common shareholders.
• The company is in the process of delisting from NASDAQ, which will reduce liquidity and transparency for U.S.-based investors.

Risks

• Potential loss of U.S. investor base and liquidity following the voluntary delisting from NASDAQ.
• Ongoing administrative and legal costs associated with the transition and potential deregistration process.
• Reliance on transitional advisory services between Puccetti and Nour to manage the orderly transition of client assets.

Future Outlook

The company intends to continue its efforts to deregister from the U.S. Securities Exchange Act of 1934 and terminate its reporting obligations with the SEC, following its delisting from NASDAQ.

Management Comments

• The Reconstituted Board intends to actively review the Issuer's prospects and opportunities to create value for shareholders.
• Puccetti's advisory roles following the sale are administrative and do not grant him voting or dispositive power over the Issuer's securities.

Industry Context

StockSavvy.ai notes that the company is following a trend of small-cap biopharma firms delisting from U.S. exchanges to avoid the high compliance costs of SEC reporting, particularly when the majority of their operations or shareholder base may be outside the U.S.

Comparison to Industry Standards

• The move to delist from NASDAQ is consistent with other micro-cap companies seeking to reduce G&A expenses.
• The board reconstitution via a resolution agreement is a standard mechanism in Canadian corporate law to resolve activist-led proxy contests.

Corporate Governance

Legal Proceedings

• The filing references a Resolution Agreement dated May 30, 2025, which settled potential proxy contest matters.

Related Party Transactions

• Peter Puccetti, as interim CEO and Chairman, maintains a consultative relationship with Nour Private Management regarding the shares held by Goodwood Fund.

Stakeholder Impact

• Shareholders face reduced liquidity due to the NASDAQ delisting.
• Clients of Goodwood are undergoing a transition to alternative investment advisors.

Next Steps

• Finalize the termination or suspension of U.S. reporting obligations under the Exchange Act.
• Continue transitional advisory services between Peter Puccetti and Nour Private Management.

Key Dates

Recommendation

The company is in a state of transition with a focus on cost-cutting and delisting. Investors should wait for clarity on the long-term strategic plan from the reconstituted board before increasing exposure.

Keywords

Cosciens Biopharma, Schedule 13D, Peter Puccetti, Corporate Governance, NASDAQ Delisting, Shareholder Activism